Expression of the B7/BB1 activation antigen and its ligand CD28 in T-cell-mediated skin diseases - PubMed (original) (raw)
Expression of the B7/BB1 activation antigen and its ligand CD28 in T-cell-mediated skin diseases
J C Simon et al. J Invest Dermatol. 1994 Oct.
Free article
Abstract
Interactions of CD28 (on T cells) with its recently identified ligand B7/BB1 (on antigen-presenting cells) have been shown to activate T cells via a major histocompatibility complex/Ag-independent "alternative" pathway, leading to an amplification of T-cell-mediated immune responses. The in vivo relevance of these molecules for cutaneous immunity is presently unknown. These findings prompted us to study the expression of B7/BB1 and CD28 in normal human skin and in selected T-cell-mediated inflammatory skin diseases. Biopsies were obtained from lesional skin of patients with allergic contact dermatitis, lichen planus, and, as control, from basal cell carcinoma and from healthy controls. Serial cryostat sections were stained with a panel of MoAbs directed against CD28, B7/BB1, CD3, CD1a, and KiM8 using immunohistochemistry (ABC technique). CD28 expression was observed in the majority of dermal and epidermal CD3+ T cells in contact dermatitis and lichen planus. In normal skin and basal cell carcinoma, CD28 was expressed only occasionally by perivascular T cells. In allergic contact dermatitis and lichen planus, B7/BB1-expression was found on dermal dendritic cells, on dermal macrophages, on Langerhans cells, focally on keratinocytes, and occasionally on dermal T cells. No B7/BB1 immunoreactivity was detected in normal skin and basal cell carcinoma. These findings indicate that T-cell-mediated skin diseases are accompanied by an influx of CD28+ T cells and an upregulation of B7/BB1 on cutaneous antigen-presenting cells, keratinocytes, and on some T cells. We speculate that "alternative" T cell-activation via the B7/CD28 pathway may contribute to the pathogenesis of these skin diseases.
Similar articles
- B7/BB1 provides an important costimulatory signal for CD3-mediated T lymphocyte proliferation in patients with systemic lupus erythematosus (SLE).
Sfikakis PP, Oglesby R, Sfikakis P, Tsokos GC. Sfikakis PP, et al. Clin Exp Immunol. 1994 Apr;96(1):8-14. doi: 10.1111/j.1365-2249.1994.tb06221.x. Clin Exp Immunol. 1994. PMID: 7512010 Free PMC article. - T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1: a ligand for CD28.
Nickoloff BJ, Nestle FO, Zheng XG, Turka LA. Nickoloff BJ, et al. Blood. 1994 May 1;83(9):2580-6. Blood. 1994. PMID: 7513205 - The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells.
Koulova L, Clark EA, Shu G, Dupont B. Koulova L, et al. J Exp Med. 1991 Mar 1;173(3):759-62. doi: 10.1084/jem.173.3.759. J Exp Med. 1991. PMID: 1847724 Free PMC article. - The CD28-B7 costimulatory pathway and its role in autoimmune disease.
Daikh D, Wofsy D, Imboden JB. Daikh D, et al. J Leukoc Biol. 1997 Aug;62(2):156-62. doi: 10.1002/jlb.62.2.156. J Leukoc Biol. 1997. PMID: 9261329 Review. - Potential roles of the B7 and CD28 receptor families in autoimmunity and immune evasion.
Harlan DM, Abe R, Lee KP, June CH. Harlan DM, et al. Clin Immunol Immunopathol. 1995 May;75(2):99-111. doi: 10.1006/clin.1995.1058. Clin Immunol Immunopathol. 1995. PMID: 7535672 Review.
Cited by
- In vivo siRNA targeting of CD28 reduces UV-induced DNA damage and inflammation.
Singh TP, Mayer G, Wolf P. Singh TP, et al. J Invest Dermatol. 2014 Mar;134(3):861-864. doi: 10.1038/jid.2013.397. Epub 2013 Sep 16. J Invest Dermatol. 2014. PMID: 24042341 No abstract available. - Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis.
Marckmann S, Wiesemann E, Hilse R, Trebst C, Stangel M, Windhagen A. Marckmann S, et al. Clin Exp Immunol. 2004 Dec;138(3):499-506. doi: 10.1111/j.1365-2249.2004.02624.x. Clin Exp Immunol. 2004. PMID: 15544628 Free PMC article. - Langerhans' cells in the murine oral mucosa in the inductive phase of delayed type hypersensitivity with 1-chloro-2, 4-dinitrobenzene.
Okamura T, Morimoto M, Yamane G, Takahashi S. Okamura T, et al. Clin Exp Immunol. 2003 Nov;134(2):188-94. doi: 10.1046/j.1365-2249.2003.02277.x. Clin Exp Immunol. 2003. PMID: 14616776 Free PMC article. - Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies.
Murata K, Dalakas MC. Murata K, et al. Am J Pathol. 1999 Aug;155(2):453-60. doi: 10.1016/s0002-9440(10)65141-3. Am J Pathol. 1999. PMID: 10433938 Free PMC article. - An essential role for CD44 variant isoforms in epidermal Langerhans cell and blood dendritic cell function.
Weiss JM, Sleeman J, Renkl AC, Dittmar H, Termeer CC, Taxis S, Howells N, Hofmann M, Köhler G, Schöpf E, Ponta H, Herrlich P, Simon JC. Weiss JM, et al. J Cell Biol. 1997 Jun 2;137(5):1137-47. doi: 10.1083/jcb.137.5.1137. J Cell Biol. 1997. PMID: 9166413 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous